Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam

Sponsor
International Vaccine Institute (Other)
Overall Status
Completed
CT.gov ID
NCT00131820
Collaborator
National Institute of Hygiene and Epidemiology, Vietnam (Other), Hue Preventive Medicine Center, Vietnam (Other), Wellcome Trust (Other), University of Western Ontario, Canada (Other), GlaxoSmithKline (Industry)
100,742
1
61
1651.2

Study Details

Study Description

Brief Summary

This study is part of International Vaccine Institutes (IVI)'s typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries. The primary objectives of the study are to evaluate the logistic feasibility of a mass typhoid fever immunization campaign program targeting school age children in Hue City, Vietnam and to assess the knowledge, attitudes, beliefs, and practices of parents and healthcare providers in Hue City regarding typhoid fever prevention and treatment.

Condition or Disease Intervention/Treatment Phase
  • Biological: Typhoid Vi vaccine
  • Biological: Hepatitis A (control)
Phase 4

Detailed Description

Typhoid fever is a major cause of morbidity worldwide. The disease predominantly affects school-aged children, is more prevalent in urban areas, may last for several weeks and can lead to serious complications. Management of this disease is further complicated by the emergence of multi-drug resistant strains. Vaccination of high risk populations is considered the most promising strategy for the control of typhoid fever. The Vi polysaccharide vaccine has been targeted for accelerated introduction into public health programs due to the following reasons: it has been shown to have consistent efficacy results even in areas of high typhoid incidence, is given as a single dose, lacks patent protection and requires less strict cold chain requirements. A cluster-randomized trial involving the Vi polysaccharide vaccine and an active control (Hepatitis A) was designed to determine the logistic feasibility of providing Vi vaccine under actual programmatic conditions among school students in Hue City. The vaccines used in this study are internationally produced and locally licensed.

Secondary objectives of this trial are:
  • To estimate the cost-effectiveness (cost of illness, willingness to pay, vaccine delivery costs, private vaccine costs, etc) of Vi vaccination

  • To determine the effectiveness of the Vi polysaccharide vaccine following routine administration of a 1-dose schedule to school students (aged >=6 years)

  • To determine the safety and immunogenicity of the Vi vaccine

  • To study typhoid risk factors among students

A nested, prospective matched case-control study is included in the trial in order to study typhoid risk factors among children in Hue City.

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
Double
Primary Purpose:
Prevention
Official Title:
Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam. An Evaluation of Feasibility, Public Acceptability, Effectiveness and Cost-Effectiveness in Students
Study Start Date :
Dec 1, 2001
Actual Primary Completion Date :
Jan 1, 2007
Actual Study Completion Date :
Jan 1, 2007

Outcome Measures

Primary Outcome Measures

  1. Logistic feasibility of mass typhoid immunization campaign []

  2. Knowledge attitudes, beliefs and practices of parents and health care providers on typhoid fever prevention and treatment []

Secondary Outcome Measures

  1. Cost-effectiveness of vaccine []

  2. Vaccine effectiveness []

  3. Adverse events []

  4. Typhoid risk factors []

Eligibility Criteria

Criteria

Ages Eligible for Study:
5 Years to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Local students whose parents/guardians provide written consent to receive Vi vaccine

  • Attending any of the 66 registered schools in Hue

  • Registered in the project census

  • Lives in Hue City

Exclusion Criteria:
  • Fever (>37.5 degrees Celsius, axillary)

  • Pregnancy

  • Lactating

Contacts and Locations

Locations

Site City State Country Postal Code
1 National Institute of Hygiene and Epidemiology Hanoi Vietnam

Sponsors and Collaborators

  • International Vaccine Institute
  • National Institute of Hygiene and Epidemiology, Vietnam
  • Hue Preventive Medicine Center, Vietnam
  • Wellcome Trust
  • University of Western Ontario, Canada
  • GlaxoSmithKline

Investigators

  • Principal Investigator: Canh G Do, MD, National Institute of Hygiene and Epidemiology, Vietnam

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00131820
Other Study ID Numbers:
  • T-14
First Posted:
Aug 19, 2005
Last Update Posted:
Mar 13, 2008
Last Verified:
Mar 1, 2008
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 13, 2008